Efficacy and safety of immune checkpoint inhibitors in patients with advanced non–small cell lung cancer (NSCLC): a systematic literature review-Reference-Cited by-同舟云学术

Efficacy and safety of immune checkpoint inhibitors in patients with advanced non–small cell lung cancer (NSCLC): a systematic literature review

Author:

Wagner Gernot¹,Stollenwerk Hannah Karolina²,Klerings Irma¹,Pecherstorfer Martin³,Gartlehner Gerald¹⁴,Singer Josef³^ORCID

Affiliation:

1. Department for Evidence-based Medicine and Evaluation, Danube University Krems, Krems, Austria

2. Karl Landsteiner University of Health Sciences, Krems, Austria

3. Division of Internal Medicine 2, Karl Landsteiner University of Health Sciences, University Hospital Krems, Krems, Austria

4. RTI International, Research Triangle Park, Durham, NC, USA

Funder

no funding for this work

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

Reference58 articles.

1. GLOBOCAN. Global cancer observatory. GLOBOCAN; 2018 [accessed 2019 Mar 07]. https://gco.iarc.fr.

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献